AstraZeneca PLC Stock price

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:12 2024-02-23 EST 5-day change 1st Jan Change
10,220 GBX +1.83% Intraday chart for AstraZeneca PLC +1.25% -3.58%
Sales 2024 * 50.92B 68.76B Sales 2025 * 54.6B 73.72B Capitalization 197B 266B
Net income 2024 * 8.61B 11.62B Net income 2025 * 10.06B 13.58B EV / Sales 2024 * 4.22 x
Net Debt 2024 * 18B 24.31B Net Debt 2025 * 12.07B 16.3B EV / Sales 2025 * 3.82 x
P/E ratio 2024 *
22.2 x
P/E ratio 2025 *
19 x
Employees 89,900
Yield 2024 *
2.46%
Yield 2025 *
2.58%
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.22%
1 week+1.25%
Current month-2.67%
1 month-2.22%
3 months+0.45%
6 months-5.11%
Current year-3.58%
More quotes
1 week
9 822.00
Extreme 9822
10 498.00
1 month
9 461.00
Extreme 9461
10 682.00
Current year
9 461.00
Extreme 9461
11 022.00
1 year
9 461.00
Extreme 9461
12 392.00
3 years
6 736.00
Extreme 6736
12 392.00
5 years
5 626.00
Extreme 5626
12 392.00
10 years
3 680.00
Extreme 3680
12 392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 12-09-30
Director of Finance/CFO 50 21-07-31
Chief Tech/Sci/R&D Officer 56 19-12-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Corporate Officer/Principal 59 13-01-31
Director/Board Member 63 17-04-26
More insiders
Date Price Change Volume
24-02-23 10,220 +1.83% 1 490 945
24-02-22 10,036 -0.65% 8,891,048
24-02-21 10,102 -1.00% 1,580,412
24-02-20 10,204 -2.05% 2,386,943
24-02-19 10,418 +3.21% 1,881,312

Delayed Quote London S.E., February 23, 2024 at 11:35 am

More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
129.5 USD
Average target price
161.8 USD
Spread / Average Target
+24.89%
Consensus
1st Jan change Capi.
-3.58% 197 B $
+31.31% 693 B $
+21.62% 552 B $
+2.97% 386 B $
+18.26% 328 B $
+14.55% 312 B $
+7.97% 210 B $
-4.95% 209 B $
-3.53% 156 B $
+0.33% 153 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer